These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 19200869

  • 1. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 2. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct 01; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 3. Future neuroprotective strategies.
    Sättler MB, Bähr M.
    Exp Neurol; 2010 Sep 01; 225(1):40-7. PubMed ID: 19716365
    [Abstract] [Full Text] [Related]

  • 4. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F, Kieseier BC.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract] [Full Text] [Related]

  • 5. The pathology of MS: new insights and potential clinical applications.
    Pittock SJ, Lucchinetti CF.
    Neurologist; 2007 Mar 01; 13(2):45-56. PubMed ID: 17351524
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O, Kieseier B, Hartung HP.
    Trends Neurosci; 2010 Mar 01; 33(3):140-52. PubMed ID: 20045200
    [Abstract] [Full Text] [Related]

  • 7. New options for early treatment of multiple sclerosis.
    Tintoré M.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [Abstract] [Full Text] [Related]

  • 8. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 01; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

  • 9. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R, Arnon R.
    Drug News Perspect; 2009 Jan 01; 22(6):301-12. PubMed ID: 19771319
    [Abstract] [Full Text] [Related]

  • 10. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS.
    Adv Neurol; 2006 Jan 01; 98():273-92. PubMed ID: 16400839
    [Abstract] [Full Text] [Related]

  • 11. Knowns and unknowns in the future of multiple sclerosis treatment.
    Stüve O.
    J Neurol Sci; 2009 Dec 01; 287 Suppl 1():S30-6. PubMed ID: 20106346
    [Abstract] [Full Text] [Related]

  • 12. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
    Lopez-Diego RS, Weiner HL.
    Nat Rev Drug Discov; 2008 Nov 01; 7(11):909-25. PubMed ID: 18974749
    [Abstract] [Full Text] [Related]

  • 13. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B, Tremlett H.
    Neurology; 2005 Mar 08; 64(5):778-9. PubMed ID: 15753408
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunomodulatory drug treatment in multiple sclerosis.
    Aharoni R.
    Expert Rev Neurother; 2010 Sep 08; 10(9):1423-36. PubMed ID: 20819013
    [Abstract] [Full Text] [Related]

  • 16. Central nervous system infections - a potential complication of systemic immunotherapy.
    Hemmer B, Frohman E, Hartung HP, Stüve O.
    Curr Opin Neurol; 2006 Jun 08; 19(3):271-6. PubMed ID: 16702834
    [Abstract] [Full Text] [Related]

  • 17. Advancement of therapies for neuroprotection in multiple sclerosis.
    Lo A.
    Expert Rev Neurother; 2008 Sep 08; 8(9):1355-66. PubMed ID: 18759548
    [Abstract] [Full Text] [Related]

  • 18. Prospects of repair in multiple sclerosis.
    Yong VW.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S16-8. PubMed ID: 19200859
    [Abstract] [Full Text] [Related]

  • 19. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J, Lublin FD.
    Adv Neurol; 2006 Feb 01; 98():257-71. PubMed ID: 16400838
    [No Abstract] [Full Text] [Related]

  • 20. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, Probert L.
    Neurodegener Dis; 2008 Feb 01; 5(1):32-7. PubMed ID: 18075273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.